PE20061054A1 - Derivados de l- leucinamida como inhibidores de cisteinproteasas - Google Patents

Derivados de l- leucinamida como inhibidores de cisteinproteasas

Info

Publication number
PE20061054A1
PE20061054A1 PE2005001349A PE2005001349A PE20061054A1 PE 20061054 A1 PE20061054 A1 PE 20061054A1 PE 2005001349 A PE2005001349 A PE 2005001349A PE 2005001349 A PE2005001349 A PE 2005001349A PE 20061054 A1 PE20061054 A1 PE 20061054A1
Authority
PE
Peru
Prior art keywords
leucinamide
alkyl
trifluoro
cysteinprotease
derivatives
Prior art date
Application number
PE2005001349A
Other languages
English (en)
Inventor
Jacques Yves Gauthier
Chun Sing Li
Christophe Mellon
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of PE20061054A1 publication Critical patent/PE20061054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) Y DERIVADOS DE N-OXIDOS DONDE R1 Y R2 SE TOMAN CONJUNTAMENTE CON EL ATOMO DE CARBONO AL CUAL ESTAN UNIDOS PARA FORMAR UN CICLOALQUILO(C3-C4); R3 ES ALQUILO(C1-C6); R4 ES ALQUILO(C1-C6); R5 ES H O ALQUILO(C1-C6), R6 ES H O ALQUILO(C1-C6); R7 ES ALQUILO(C1-C6); D ES ARILO O HETEROARILO; n ES 2. SON COMPUESTOS PREFERIDOS: N1-(1-CIANOCICLOPROPIL)-N2-(1-{4'-[2,2-DIFLUORO-1-HIDROXIETIL]BIFENIL-4-IL}-2,2,2-TRIFLUOROETIL)-4-FLUORO-L-LEUCINAMIDA, N1-(1-CIANOCICLOPROPIL)-4-FLUORO-N2-{2,2,2-TRIFLUORO-1-[4'-(2,2,2-TRIFLUORO-1-HIDROXIETIL)BIFENIL-4-IL]ETIL}-L-LEUCINAMIDA, N1-(1-CIANOCICLOPROPIL)-4-FLUORO-N2-(2,2,2-TRIFLUORO-1-{4'-[3,3,3-TRIFLUORO-1-HIDROXI-1-METILPROPIL]BIFENIL-4-IL}ETIL)-L-LEUCINAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA CISTEINPROTEASA COMO LAS CATEPSINAS K, L, S Y B SIENDO UTILES EN EL TRATAMIENTO DE OSTEOPOROSIS, ARTRITIS REUMATOIDE, OSTEOARTRITIS
PE2005001349A 2004-11-23 2005-11-17 Derivados de l- leucinamida como inhibidores de cisteinproteasas PE20061054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63040504P 2004-11-23 2004-11-23

Publications (1)

Publication Number Publication Date
PE20061054A1 true PE20061054A1 (es) 2006-10-20

Family

ID=36497694

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001349A PE20061054A1 (es) 2004-11-23 2005-11-17 Derivados de l- leucinamida como inhibidores de cisteinproteasas

Country Status (24)

Country Link
US (2) US7407959B2 (es)
EP (1) EP1817276B1 (es)
JP (1) JP5055488B2 (es)
KR (1) KR20070085435A (es)
CN (2) CN102391151A (es)
AR (1) AR055283A1 (es)
AU (1) AU2005309267B2 (es)
BR (1) BRPI0518054A (es)
CA (1) CA2589085C (es)
DK (1) DK1817276T3 (es)
ES (1) ES2394618T3 (es)
IL (1) IL183308A (es)
MX (1) MX2007006136A (es)
MY (1) MY137717A (es)
NO (1) NO339125B1 (es)
NZ (1) NZ554872A (es)
PE (1) PE20061054A1 (es)
PL (1) PL1817276T3 (es)
PT (1) PT1817276E (es)
RU (1) RU2399613C2 (es)
SI (1) SI1817276T1 (es)
TW (1) TWI353244B (es)
WO (1) WO2006056047A1 (es)
ZA (1) ZA200703530B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163748A0 (en) * 2002-03-05 2005-12-18 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
TW200524851A (en) * 2003-09-18 2005-08-01 Axys Pharm Inc Haloalkyl containing compounds as cysteine protease inhibitors
US8013186B2 (en) * 2004-12-01 2011-09-06 Virobay, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
JP5154944B2 (ja) * 2004-12-02 2013-02-27 ビロベイ，インコーポレイティド システインプロテアーゼインヒビターとしてのスルホンアミド含有化合物
WO2006076796A1 (en) * 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and obesity
SI1855674T1 (sl) * 2005-03-02 2014-10-30 Merck Sharp & Dohme Corp. Sestavek za inhibicijo katepsina k
EA017874B1 (ru) * 2005-03-21 2013-03-29 Вайробей, Инк. Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз
MX2007011739A (es) * 2005-03-22 2008-03-14 Celera Genomics Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
EP2077869B1 (en) * 2006-08-28 2015-02-25 Akademia Medyczna Im. Piastow Slaskich We Wroclaw iu A system for the extra-corporeal purification of blood of pathogenic enzymes
US20100048717A1 (en) * 2006-09-25 2010-02-25 MERCK FROSST CANADA LTD, Merk & Co., Inc. Cathepsin b inhibitors
MX2009003563A (es) * 2006-10-04 2009-04-15 Virobay Inc Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
US7893112B2 (en) 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
WO2009065098A1 (en) * 2007-11-16 2009-05-22 Velcura Therapeutics, Inc. Use of cathepsin k antagonists in the treatment of bone cancer
CA2743749A1 (en) * 2008-11-13 2010-05-20 Virobay, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
US8324417B2 (en) * 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
CN106916091B (zh) * 2015-12-24 2020-10-09 广东东阳光药业有限公司 组织蛋白酶k抑制剂及其用途
US10758559B1 (en) * 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
JP2021533122A (ja) 2018-08-02 2021-12-02 インターベット インターナショナル ベー． フェー． 選択的カテプシンシステインプロテアーゼ阻害剤を製造する方法
CN112912367A (zh) * 2018-08-02 2021-06-04 英特维特国际股份有限公司 N1-(1-氰基环丙基)-n2-((1s)-1-{4′-[(1r-2,2-二氟-1-羟基乙基]联苯基-4-基}-2,2,2-三氟乙基)-4-氟-l-亮氨酸酰胺的结晶形式
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
CN112438972B (zh) * 2019-08-29 2021-07-30 沈阳药科大学 组织蛋白酶抑制剂的医药用途
CN113462728B (zh) * 2021-07-09 2024-06-07 浙江工业大学 一种利用土星轮头酵母制备(r)-1-(4-溴苯基)-2,2,2-三氟乙醇的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841871D1 (en) 1997-11-05 2010-10-14 Novartis Ag Dipeptide nitrile
AU2002254099B2 (en) * 2001-03-02 2006-07-06 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
US7302587B2 (en) * 2001-06-08 2007-11-27 Matra Transport International Secure computer system
JP4343690B2 (ja) * 2001-11-13 2009-10-14 メルク フロスト カナダ リミテツド プロテアーゼ阻害薬としてのシアノアルキルアミノ誘導体
IL163748A0 (en) * 2002-03-05 2005-12-18 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
WO2004052921A1 (en) * 2002-12-05 2004-06-24 Axys Pharmaceuticals, Inc. Cyanomethyl derivatives as cysteine protease inhibitors
TW200524851A (en) * 2003-09-18 2005-08-01 Axys Pharm Inc Haloalkyl containing compounds as cysteine protease inhibitors
SI1855674T1 (sl) * 2005-03-02 2014-10-30 Merck Sharp & Dohme Corp. Sestavek za inhibicijo katepsina k

Also Published As

Publication number Publication date
AU2005309267A1 (en) 2006-06-01
KR20070085435A (ko) 2007-08-27
TWI353244B (en) 2011-12-01
AU2005309267B2 (en) 2011-05-12
RU2007123611A (ru) 2008-12-27
EP1817276B1 (en) 2012-08-08
PL1817276T3 (pl) 2012-12-31
NZ554872A (en) 2010-12-24
ZA200703530B (en) 2008-01-08
SI1817276T1 (sl) 2012-12-31
IL183308A0 (en) 2007-09-20
PT1817276E (pt) 2012-10-25
ES2394618T3 (es) 2013-02-04
MY137717A (en) 2009-03-31
NO20073222L (no) 2007-08-03
TW200631576A (en) 2006-09-16
JP2008520590A (ja) 2008-06-19
US20060111440A1 (en) 2006-05-25
RU2399613C2 (ru) 2010-09-20
EP1817276A4 (en) 2009-12-09
US7407959B2 (en) 2008-08-05
CN102391151A (zh) 2012-03-28
EP1817276A1 (en) 2007-08-15
AR055283A1 (es) 2007-08-15
WO2006056047A1 (en) 2006-06-01
CN101061093A (zh) 2007-10-24
US20070293578A1 (en) 2007-12-20
MX2007006136A (es) 2007-07-19
NO339125B1 (no) 2016-11-14
IL183308A (en) 2013-05-30
BRPI0518054A (pt) 2008-10-28
JP5055488B2 (ja) 2012-10-24
DK1817276T3 (da) 2012-11-19
WO2006056047A9 (en) 2007-06-21
CA2589085A1 (en) 2006-06-01
CA2589085C (en) 2014-04-29

Similar Documents

Publication Publication Date Title
PE20061054A1 (es) Derivados de l- leucinamida como inhibidores de cisteinproteasas
ECSP066858A (es) Inhibidores de gsk-3
NO20065178L (no) Tienopyridinderivater
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
PE20070318A1 (es) Metodo para purificar tigeciclina
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
BR0308261A (pt) Métodos extrativos para puruficação de sucralose
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
BRPI0510260A (pt) método para purificar um composto, e, kit farmacêutico
PE20070009A1 (es) Tigeciclina y metodos para su preparacion
DK1506203T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf
PE20060583A1 (es) Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas
CR7950A (es) Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas
GT200500296A (es) Sintesis asimetrica de derivados del dehidrobenzofurano
NO20061872L (no) Disulfid, sulfid, sulfoksid, og sulfoderivater av sykliske sukkere og anvendelse derav
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
CR8350A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica
AR050250A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica
ATE540667T1 (de) Verbindungen mit kühlender wirkung
CY1109740T1 (el) Νεα μεθοδος συνθεσης παραγωγων της 1,3,4,5 -τετραϋδρο-2η- 3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης της σε ενα φαρμακευτικως αποδεκτο οξυ
EA200602281A1 (ru) Гетероарилсульфоны и сульфонамиды и их терапевтические применения
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
AR040968A1 (es) Bifenilcarboxamidas sustituidas con n- aril piperidina, un metodo para su preparacion, composicion farmaceutica y proceso de preparacion
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed